ArticleBMC gastroenterology2026
Long-term clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma: a retrospective study in regions with a high prevalence of Helicobacter pylori infection.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThis study aims to investigate the treatment outcomes and identify risk factors influencing complete remission (CR) and relapse in patients with gastric MALT lymphoma across different treatment modalities.
methodsThree-hundred and ninety-eight patients with gastric MALT lymphoma were followed up for at least 48 weeks over 15 years in five tertiary hospitals in regions with high prevalence of Helicobacter pylori (H. pylori) infection. A retrospective review was performed using medical records.
resultsA total of 398 patients were included, with a mean age at diagnosis of 55.5 ± 12.2 years and 176 (44.2%) were male. H. pylori infection was identified in 293 patients (73.6%), and 363 (91.2%) were diagnosed with stage IE. Significant differences in age, sex, and stage at diagnosis were observed between H. pylori-positive (HPP) and H. pylori-negative groups (HPN, all P < 0.05). In the HPP group, most patients underwent eradication therapy (98.9%), whereas 77.3% of HPN patients received eradication therapy, often combined with radiotherapy or chemotherapy. CR rate was 97.0%, with 98.3% in HPP and 93.3% in HPN (P = 0.018). During a median follow-up of 179 weeks, relapse occurred in 8.3% of patients, with 7.9% in HPP and 10.2% in HPN, respectively. Non-IE Modified Ann Arbor Stage (HR, 2.4; 95% CI, 1.0–5.5; P = 0.044), presence of lymphadenopathy (HR, 1.9; 95% CI, 1.2–3.1; P = 0.010), and lesions in multiple locations (HR, 2.1; 95% CI, 1.0 ~ 4.2; P = 0.037) at diagnosis correlated with a higher cumulative incidence of relapse (CIR). Multivariate Cox regression analysis showed that Non-IE Modified Ann Arbor Stage (aHR, 1.9; 95% CI, 1.2‒2.9; P = 0.004) and presence of lymphadenopathy (aHR, 1.5; 95% CI, 1.0‒2.3; P = 0.037) remained significantly correlated with higher CIR.
conclusionsPatients with gastric MALT lymphoma generally have a favorable prognosis, and H. pylori eradication can lead to CR, even in H. pylori-negative MALT lymphoma cases. Accurate staging at diagnosis is essential for optimal management, as disease stage and the presence of lymphadenopathy are key predictors of relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.